Ionis Pharmaceuticals (IONS) Stock Looks Fully Priced On Sales Yet Mixed On Value

Ionis Pharmaceuticals stock has delivered a 60.7% gain over the past five years, yet current valuation checks using market multiples point to the shares screening as expensive, while the broader value score suggests a more mixed picture. After a strong multiyear run and recent share price swings, investors are weighing whether the current price fairly reflects the company’s prospects.

• A 60.7% return over five years highlights that Ionis Pharmaceuticals has already rewarded long term holders. This can reduce the margin of safety for new buyers if expectations are high.
• Upcoming data around TRYNGOLZA and follow on therapy ION775 may support sentiment toward future revenue potential. At the same time, clinical and regulatory risk around the broader pipeline can still put pressure on what investors are willing to pay.
• With a value score of 4 out of 6, the overall read is a mixed picture rather than a clear bargain or clear overvaluation.

The issue now is whether Ionis Pharmaceuticals' current valuation leaves enough upside potential to compensate for the risks that come with its drug development pipeline.

Scan beyond Ionis Pharmaceuticals by reviewing hand picked biotechs and healthcare stocks with potential valuation gaps in the 45 high quality undervalued stocks.

Is Ionis Pharmaceuticals Getting Expensive on Sales?

P/S is often the cleaner yardstick for Ionis Pharmaceuticals because the company is still working through losses, so earnings-based ratios like P/E are less informative.

The stock currently trades on a P/S of 11.5x. This is below the average P/S of 13.1x for the wider biotechs industry and also below the peer group average of 15.8x. However, the tailored fair P/S multiple for Ionis Pharmaceuticals is 4.0x, which is much lower than where the stock trades today.

Despite the recent attention around TRYNGOLZA and its follow-on therapy, the current P/S still prices Ionis Pharmaceuticals well above the level implied by this fair multiple, so the shares screen as expensive on this framework.

On the preferred P/S yardstick, Ionis Pharmaceuticals stock appears overvalued relative to the fair multiple suggested by its profile.

See what the numbers say about this price — find out in our valuation breakdown.

The Ionis Pharmaceuticals Narrative: What Would Justify Today's Price?

Simply Wall St Narratives for Ionis Pharmaceuticals pick up where the earlier valuation puzzle leaves off. They spell out in plain terms what would need to happen to Ionis Pharmaceuticals' future growth, margins and earnings for the stock to be worth materially more or less than today’s price, and show how each valuation number rests on specific future paths that you can then watch over time.

One of the top community narratives on Ionis Pharmaceuticals: 31% undervalued

"Expanding into larger patient populations and strong physician acceptance position Ionis for substantial market share gains and sustained top-line growth..."

Read one of the top narratives on Ionis Pharmaceuticals

Do you think there's more to the story for Ionis Pharmaceuticals? Head over to our Community to see what others are saying!

The Bottom Line

On the current numbers, Ionis Pharmaceuticals screens as overvalued on sales based on its tailored P/S multiple, even though the wider valuation checks are not outright negative. That leaves the stock leaning more toward optimism than clear mispricing. The key question from here is whether future revenue and pipeline progress can grow into the existing P/S, or whether sentiment cools and the multiple settles closer to the suggested fair level.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com